| Specification: |
Pituitary growth hormone , with CAS number of 9002-72-6, can be called adenohypophysealgrowthhormone ; hormonesomatotrope ; anteriorpituitarygrowthhormone ; hypophysealgrowthhormone ; phyol ; phyone ; pituitarygrowthhormone ; somacton .
Pituitary growth hormone (CAS NO.9002-72-6) can be used to treat conditions that produce short stature but are not related to deficiencies. However, results are not as dramatic when compared to short stature that is solely due to deficiency of GH. Examples of other causes of shortness often treated with Somatotropin are Turner syndrome, chronic renal failure, Prader-Willi syndrome, intrauterine growth retardation, and severe idiopathic short stature. Higher pharmacologic doses are required to produce significant acceleration of growth in these conditions, producing blood levels well above normal.
Despite the higher doses, side-effects during treatment are rare, and vary little according to the condition being treated. Somatotropin treatment improves muscle strength and slightly reduces body fat in Prader-Willi syndrome, which are significant concerns beyond the need to increase height. Somatotropin is also useful in maintaining muscle mass in wasting due to AIDS. Somatotropin can also be used in patients with short bowel syndrome to lessen the requirement for intravenous total parenteral nutrition. Somatotropin can also be used for conditions that do not cause short stature. Typically, growth hormone treatment for conditions unrelated to stature is controversial and experimental. Somatotropin has been used for remission of multiple sclerosis, to reverse the effects of aging in older adults (see below), to enhance weight loss in obesity, as well as fibromyalgia, heart failure, Crohn's disease and ulcerative colitis, burns and bodybuilding or athletic enhancement.
|
